Peptide Polymorphism Screening Outsourcing Services - Identify Solid-State Forms Before They Surprise You

Your peptide API passed all release testing. Purity, identity, potency, everything within specification. Six months later, a stability sample shows unexpected changes in dissolution behavior. Investigation reveals that your peptide has converted to a different crystalline form during storage, one with different dissolution properties and potentially different bioavailability.

Polymorphism, the ability of a molecule to exist in multiple solid-state forms, is not limited to small molecules. Peptides can exhibit polymorphism, form hydrates and solvates, and exist as amorphous versus crystalline solids. Each form may have different stability, solubility, dissolution rate, and manufacturability characteristics.

Peptide polymorphism screening outsourcing services engage specialized solid-state chemistry laboratories to systematically identify all accessible solid forms of your peptide API. This knowledge, gained early in development, prevents the costly surprises that uncontrolled form changes create later in your program.

What Is Peptide Polymorphism Screening?

Peptide polymorphism screening outsourcing services encompass the engagement of specialized solid-state chemistry laboratories to conduct systematic investigations of the solid-state landscape of peptide drug substances. This work identifies all thermodynamically and kinetically accessible solid forms and characterizes their relative stability, interconversion behavior, and physicochemical properties.

The screening process involves exposing the peptide to a wide range of crystallization conditions: different solvents, solvent mixtures, temperatures, pH values, evaporation rates, and anti-solvent addition protocols. Each experiment is designed to access different regions of the polymorphic landscape. The resulting solids are characterized by X-ray powder diffraction (XRPD), differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and spectroscopic methods (Raman, FTIR).

For peptides, the solid-state picture can be more complex than for small molecules. Many peptides exist primarily as amorphous solids, which have different stability and handling characteristics than crystalline forms. Some peptides form hydrates or solvates that can convert to different forms upon drying or exposure to humidity.

Lyophilized peptides may exhibit different solid-state behavior depending on lyophilization cycle parameters.

Outsourcing partners maintain the specialized equipment (powder X-ray diffractometers, DSC instruments, dynamic vapor sorption analyzers, single-crystal X-ray capability) and experienced solid-state scientists required to conduct comprehensive polymorph screens and interpret the results.

Stephen Byrn, Professor of Medicinal Chemistry, Purdue University, "Solid-State Chemistry of Drugs": "Solid-state form selection is one of the most consequential decisions in drug development, yet it is often treated as an afterthought until a crisis forces attention"

Why It Matters

Uncontrolled polymorphic transitions are regulatory and commercial nightmares. A form change during manufacturing can alter your peptide's dissolution behavior, potentially affecting bioavailability. A form change during storage can invalidate your stability data and require revised shelf life assignments.

A form change discovered after NDA filing can trigger a complete response letter requiring additional studies.

The regulatory expectation is clear. ICH Q6A and FDA guidance on ANDAs both require sponsors to characterize the polymorphic form of their drug substance and demonstrate control of form throughout manufacturing and storage. For peptide drug substances, this means showing that your manufacturing process consistently produces the intended form and that the form remains stable under your specified storage conditions.

The financial consequences of inadequate polymorphism control are well documented. Late-stage form changes have triggered product recalls, clinical holds, and complete reformulation campaigns in the pharmaceutical industry. The cost of a comprehensive polymorph screen early in development ($50,000 to $150,000) is trivial compared to the cost of discovering an uncontrolled form conversion after clinical development is underway.

For peptides specifically, the lyophilization step presents particular polymorphism risk. The solid form produced during lyophilization depends on formulation composition, freezing rate, primary drying temperature, and secondary drying conditions. Without polymorphism screening, you may not recognize that a change in your lyophilization cycle has produced a different solid form of your API.

Regulatory agencies have issued complete response letters specifically due to inadequate solid-state characterization, even when purity and potency data were fully compliant.

Benefits Checklist

• Early Risk Identification: Discover all accessible solid forms before they surprise you during manufacturing or stability studies.
• Regulatory Compliance: Meet ICH Q6A and FDA expectations for solid-state characterization in CMC filings.
• Form Selection: Choose the most stable, most manufacturable, and most bioavailable solid form for development.
• Stability Protection: Understanding form interconversion behavior prevents unexpected stability failures.
• Patent Opportunities: Novel polymorphic forms can be patented, extending intellectual property protection.
• Capital Avoidance: Eliminate $500K+ investment in XRPD, DSC, and crystallization screening equipment.
• Expert Interpretation: Solid-state scientists with peptide experience interpret complex polymorphism data and recommend development strategies.

Services Breakdown

Screening Service	Scope	Deliverables	Cost Range
Preliminary Polymorph Screen	20 to 50 crystallization experiments across common conditions	Initial form landscape, form identification	$15,000 to $30,000
Comprehensive Polymorph Screen	100 to 200+ experiments across expanded conditions	Complete form landscape, relative stability ranking	$50,000 to $100,000
Hydrate/Solvate Screening	Systematic evaluation of hydrate and solvate formation	Hydration behavior, solvate identification, stability data	$15,000 to $30,000
Amorphous Characterization	Tg determination, stability assessment, crystallization tendency	Amorphous stability report, crystallization risk assessment	$10,000 to $25,000
Form Stability Studies	Competitive slurry experiments, thermal stability, humidity stress	Thermodynamic stability ranking, form conversion map	$15,000 to $30,000
Salt/Co-Crystal Screening	Evaluation of salt forms and co-crystals for improved properties	Salt/co-crystal identification, property comparison	$30,000 to $80,000

Commission your polymorph screen before process lock, not after, so the form you select for development is the same form your manufacturing process reliably produces at scale.

Tips for Success

1. Conduct polymorphism screening during process development. Understanding your solid-state landscape early allows you to select the optimal form and design your manufacturing process to produce it consistently.

2. Screen a representative batch. The peptide used for polymorphism screening should be representative of your intended manufacturing process. Different synthesis and purification methods can produce different initial solid forms.

3. Include humidity stress in your screening. Peptides are often hygroscopic, and humidity-induced form changes (amorphous to crystalline, anhydrate to hydrate) are among the most common and problematic transitions.

4. Characterize your lyophilized product's solid state. If your drug product is lyophilized, confirm that the solid form in the lyophilized cake is consistent across batches and stable during storage. Lyophilization parameters directly influence the solid-state outcome.

5. Document the thermodynamic relationship between forms. Understanding which form is thermodynamically stable at your storage conditions informs your control strategy and specification-setting. Metastable forms require additional justification and monitoring.

6. Include solid-state characterization in your stability program. XRPD analysis at key stability time points demonstrates that your intended form is maintained throughout the product's shelf life.

7. Consider patent opportunities. Novel polymorphic forms of known peptides can be patented. If your screening identifies a new crystalline form with superior properties, discuss IP protection with your patent counsel before disclosure.

Comparison Table: No Polymorph Screening vs. Outsourced Polymorphism Screening

Factor	No Screening	Outsourced Polymorph Screen
Solid-State Knowledge	None until problems occur	Complete landscape before development
Form Change Discovery	During manufacturing or stability (crisis)	During screening (controlled)
Remediation Cost	$1M+ (reformulation, re-filing)	$50K to $150K (screening investment)
Regulatory Confidence	Low (no characterization data)	High (comprehensive data in filing)
Form Control Strategy	Absent	Defined, based on screening data
Patent Opportunities	Missed	Identified and protectable
Stability Program Design	Generic	Informed by form behavior
Manufacturing Consistency	Unknown solid-state outcome	Controlled, predictable form

Polymorphism data shapes your regulatory submission control strategy directly.

Coordinate solid-state work with process development for lyophilized products.

External Authority Link

ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products establishes the regulatory expectation for polymorphism characterization, including decision trees for when polymorphism screening is required. the ICH Q6A guidance provides the framework that regulators use to evaluate your solid-state control strategy.

Knowing every accessible solid form of your peptide API before filing is far cheaper than discovering an uncontrolled form conversion after your IND or NDA is under review.

Frequently Asked Questions

What is polymorphism and why does it matter for peptide APIs?

Polymorphism means a molecule can exist in more than one solid-state form, each with different physical properties. For peptide APIs, different forms can have different dissolution rates, stability profiles, and bioavailability, which means an uncontrolled form change can affect both product performance and regulatory compliance.

When in development should polymorphism screening be done?

Screening should happen during process development, before you lock in your manufacturing process and certainly before Phase II or III clinical trials. Finding a problematic form change after clinical development is underway is far more expensive and disruptive than discovering it early during a controlled screen.

What analytical methods are used in a polymorphism screen?

The primary tool is X-ray powder diffraction (XRPD), which identifies crystalline forms based on their unique diffraction patterns. Differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), and dynamic vapor sorption (DVS) are also used to characterize thermal behavior, moisture content, and hydration tendencies.

How much does a comprehensive peptide polymorphism screen cost?

A comprehensive screen covering 100 to 200 crystallization experiments typically costs $50,000 to $100,000. When you add hydrate and solvate screening and amorphous characterization, the total investment is usually $75,000 to $150,000, which is a small fraction of the $1 million or more it can cost to remediate a form change found after filing.

What regulatory guidance covers polymorphism requirements for drug substances?

ICH Q6A provides the primary framework for polymorphism characterization requirements, including decision trees that guide when screening is needed. FDA guidance documents for ANDAs and NDAs also address solid-state characterization expectations, and regulators can issue Complete Response Letters when polymorphism data is insufficient.

Ready to Identify All Solid-State Forms of Your Peptide?

Polymorphism is not a theoretical risk. It is a practical reality that has delayed approvals, triggered recalls, and cost companies millions. Early screening eliminates the surprise and gives you control over a variable that can otherwise derail your program.

Ready to screen? Contact PeptideStaff today for a staffing consultation. We connect peptide biotech teams with solid-state chemistry laboratories that specialize in polymorphism screening and help you build a form control strategy that satisfies regulatory expectations.